TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12173194

Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol (n = 12)
Number of subjects: 24
Study: 10634567

Group type: EXPERIMENTAL
Intervention: Visual acuity screening and complete eye examination by a pediatric ophthalmologist
Number of subjects: 6292

Group type: EXPERIMENTAL
Intervention: Traumatic cataracts noted in children
Number of subjects: 6292

Group type: EXPERIMENTAL
Intervention: Post-trauma surgery care
Number of subjects: 6292
Study: 8944090

Group type: EXPERIMENTAL
Intervention: Mipragoside 0.5% aqueous ophthalmic gel, administered four times a day for 2 weeks after a week of placebo treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mipragoside 0.5% aqueous ophthalmic gel
Number of subjects: 24
Study: 1684653

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.25 micrograms/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.50 micrograms/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 1.0 micrograms/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fentanyl (FEN) 2 micrograms/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 7120379

Group type: EXPERIMENTAL
Intervention: Bortner scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jenkins Activity Survey (JAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sandler Hazary Questionnaire and Eysenck Personality Inventory (SHEPI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social variables
Number of subjects: 0
Study: 31547944

Group type: EXPERIMENTAL
Intervention: D90 >101%
Number of subjects: 266

Group type: COMPARATOR
Intervention: D90 <101%
Number of subjects: 266
Study: 28017907

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) delivered via phone calls for 8 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 50
Study: 27931252

Group type: EXPERIMENTAL
Intervention: Advertising patient and public involvement (PPIR) using a leaflet and invitations to potential participants.
Number of subjects: 8182

Group type: COMPARATOR
Intervention: Control group (no advertising of PPIR).
Number of subjects: 8182

Group type: EXPERIMENTAL
Intervention: Advertising PPIR using a leaflet and invitations to potential participants.
Number of subjects: 8182
Study: 24919195

Group type: EXPERIMENTAL
Intervention: Low-dose protocol (100 kVp tube voltage, 100 mAs tube current, 3.2 pitch, sinogram affirmed iterative reconstruction)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control protocol (120 kVp tube voltage, 120 mAs tube current, 2.4 pitch, filtered back projection)
Number of subjects: 42
Study: 23324248

Group type: EXPERIMENTAL
Intervention: DCE plus best medical treatment (BMT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: BMT alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DCE plus BMT
Number of subjects: 28
Study: 19925464

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Basiliximab (Tac/Bas)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Tacrolimus/MMF (Tac/MMF)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Tacrolimus/MMF/steroids (Control)
Number of subjects: 451
Study: 17884451

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/d for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Untreated diabetic patients with CAD
Number of subjects: 46
Study: 15716847

Group type: EXPERIMENTAL
Intervention: Technique using an operating microscope and minimal osteotomy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Traditional technique without an operating microscope
Number of subjects: 66
Study: 12059812

Group type: EXPERIMENTAL
Intervention: Sclerotization of the varicocele
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 67
Study: 10086835

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron mesylate intravenous infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mg dolasetron mesylate intravenous infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron mesylate intravenous infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron mesylate oral administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrodolasetron (active metabolite)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrodolasetron
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dolasetron and hydrodolasetron
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 24
Study: 8589617

Group type: EXPERIMENTAL
Intervention: Normothermic isolated limb perfusion with melphalan
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Mild hyperthermic isolated limb perfusion with melphalan
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Iliac isolation level during ILP
Number of subjects: 181
Study: 2188202

Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis-component diphtheria and tetanus toxoids and pertussis vaccine (DTP)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Licensed DTP vaccine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Acellular pertussis component DTP vaccine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: DTP vaccine (in infants)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: DTP vaccine (in 4- to 6-year-old children)
Number of subjects: 7
Study: 7066739

Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular saline (placebo)
Number of subjects: 0
Study: 31340979

Group type: EXPERIMENTAL
Intervention: Two infusions of 1-g rituximab at 2-week intervals (NICE cohort)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Two infusions of 375 mg/m2 at 1-week intervals (GEMRITUX cohort)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined study population
Number of subjects: 55
Study: 27235666

Group type: EXPERIMENTAL
Intervention: DHA supplement >185 mg/day
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (no DHA supplement)
Number of subjects: 409
Study: 25820612

Group type: EXPERIMENTAL
Intervention: 3-month paliperidone palmitate (175, 263, 350, or 525 mg eq)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 23800342

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 456

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 456
Study: 21063203

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 28

Group type: COMPARATOR
Intervention: Calcium channel blocker (general)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated hypertensive patients
Number of subjects: 28
Study: 19884620

Group type: EXPERIMENTAL
Intervention: Family‐based home health education (HHE) from lay health workers every 3 months and annual training of general practitioners (GPs) in hypertension management
Number of subjects: 1341

Group type: COMPARATOR
Intervention: GP‐only, HHE‐only, or no intervention
Number of subjects: 1341
Study: 17324670

Group type: EXPERIMENTAL
Intervention: Soy-protein-rich diet (15 g soy protein/1,000 kcal daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control diet (caloric intake decreased by 500 kcal/day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Soy-protein-rich diet
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 47
Study: 16902384

Group type: EXPERIMENTAL
Intervention: Nutritional education intervention conducted by a dietician during two half‐day sessions.
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Nutritional education intervention.
Number of subjects: 236
Study: 15279619

Group type: EXPERIMENTAL
Intervention: B-group vitamin supplementation (5 mg of folate, 5 mg of vitamin B2, 50 mg of vitamin B6, 0.4 mg of vitamin B12) for 14 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: B-group vitamin supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 10939701

Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine (500 microg in 1 ml volume)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (1 ml saline)
Number of subjects: 40
Study: 9411412

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 1286502

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.67 mg IV, range 0.2 to 1 mg)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 139
Study: 3885203

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Metoprolol 200 mg daily
Number of subjects: 31
Study: 29241423

Group type: EXPERIMENTAL
Intervention: Reconsolidation of Traumatic Memories (RTM)
Number of subjects: 74
Study: 29045324

Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program (CHAMP; n = 81)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (n = 43)
Number of subjects: 124
Study: 25733342

Group type: EXPERIMENTAL
Intervention: Exercise and weight loss self-efficacy
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Weekly fruit consumption, past weight loss experience, and weight loss self-efficacy
Number of subjects: 1285
Study: 23904292

Group type: EXPERIMENTAL
Intervention: gE combined with AS01B
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: gE combined with AS01E
Number of subjects: 100

Group type: COMPARATOR
Intervention: unadjuvanted gE
Number of subjects: 100

Group type: COMPARATOR
Intervention: saline
Number of subjects: 100
Study: 21916532

Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) protocol
Number of subjects: 483

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 483
Study: 19154823

Group type: EXPERIMENTAL
Intervention: 100 mouse units (MU)/mL dilution, 0.4cc/site, 4-quadrant injection
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100 MU/mL dilution, 0.4cc/site, 4 sites along endplate band
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 20 MU/mL dilution, 2cc/site, 4-quadrant injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 17005059

Group type: EXPERIMENTAL
Intervention: Standard hygroscopic heat-and-moisture exchanger (HME) with 15-cm flexible tubing
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 15-cm flexible tubing only
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: No HME or flexible tubing
Number of subjects: 7
Study: 15510460

Group type: EXPERIMENTAL
Intervention: Modified needle drainage (MND)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional drainage (CD)
Number of subjects: 80
Study: 11157183

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg QID for 10 days
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 9633738

Group type: EXPERIMENTAL
Intervention: Tramadol (210 mg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 131
Study: 7833494

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 248

Group type: COMPARATOR
Intervention: Chlorpropamide
Number of subjects: 248

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 248

Group type: COMPARATOR
Intervention: Gliquidone
Number of subjects: 248
Study: 2979230

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: acetyl-5-aminosalicylic acid
Number of subjects: 40
Study: 30760305

Group type: EXPERIMENTAL
Intervention: Self-referral system for a brief intervention titled 'self-confidence'
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Self-referral system for a brief intervention
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Self-referral to a brief intervention for depression
Number of subjects: 459
Study: 28238058

Group type: EXPERIMENTAL
Intervention: Multimedia training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Practical training
Number of subjects: 70

Group type: COMPARATOR
Intervention: No training
Number of subjects: 70
Study: 25573751

Group type: EXPERIMENTAL
Intervention: Metformin (dosage not specified)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Metformin pharmacokinetics in GT genotype
Number of subjects: 220

Group type: COMPARATOR
Intervention: Metformin pharmacokinetics in GG genotype
Number of subjects: 220
Study: 22244715

Group type: EXPERIMENTAL
Intervention: Low-normal systolic blood pressure (<120 mm Hg)
Number of subjects: 3680

Group type: COMPARATOR
Intervention: High-normal systolic blood pressure (120 to <140 mm Hg)
Number of subjects: 3680

Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (>140 mm Hg)
Number of subjects: 3680
Study: 21691762

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 50
Study: 19061721

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of autologous bone marrow mononuclear cells
Number of subjects: 115
Study: 16487195

Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 79

Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 79
Study: 15537429

Group type: EXPERIMENTAL
Intervention: Pre-warning letter
Number of subjects: 627

Group type: COMPARATOR
Intervention: No pre-warning letter
Number of subjects: 627
Study: 11027869

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRI
Number of subjects: 500

Group type: COMPARATOR
Intervention: Two-view x-ray mammography
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: MRI examination
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Multiparametric analysis
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Retrospective analysis
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Overall diagnostic performance
Number of subjects: 500
Study: 9174449

Group type: EXPERIMENTAL
Intervention: High-vacuum drains
Number of subjects: 73

Group type: COMPARATOR
Intervention: Low-vacuum drains
Number of subjects: 73
Study: 1443704

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Propofol (all doses)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Propofol (larger doses)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg before propofol
Number of subjects: 150
Study: 2951797

Group type: EXPERIMENTAL
Intervention: Duovent (100 micrograms fenoterol and 40 micrograms ipratropium bromide per puff)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31992758

Group type: EXPERIMENTAL
Intervention: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Increase in TG by 10 mg/dL from preconception to 28 weeks
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks (for BMI ≥25)
Number of subjects: 575
Study: 29454039

Group type: EXPERIMENTAL
Intervention: 300 µg selenium/d as selenium-enriched-yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 100 µg selenium/d as selenium-enriched-yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 200 µg selenium/d as selenium-enriched-yeast
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo-yeast
Number of subjects: 491
Study: 29231404

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation
Number of subjects: 98

Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 98
Study: 23636469

Group type: EXPERIMENTAL
Intervention: isocaloric AGE‐restricted diet (<10 AGE Eq/day) for 4 months
Number of subjects: 85

Group type: COMPARATOR
Intervention: standard diet (regular >15 AGE Eq/day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Model AGEs in WT cells
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Model AGEs in AGER1(+) cells
Number of subjects: 85
Study: 23388205

Group type: EXPERIMENTAL
Intervention: Pre-biopsy educational (ED) packet containing biopsy instruction sheet and a booklet about the biopsy procedure and prostate cancer treatment decision aid
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pre-biopsy educational (ED) packet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Men diagnosed with cancer in the UC group
Number of subjects: 29
Study: 19968611

Group type: EXPERIMENTAL
Intervention: Geranylgeranylacetone (GGA) 150 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18334144

Group type: EXPERIMENTAL
Intervention: Wuling Capsule (3 capsules three times a day)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Deanxit (10.5 mg twice daily)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Wuling Capsule plus Deanxit (both treatments)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Wuling Capsule
Number of subjects: 114

Group type: COMPARATOR
Intervention: Deanxit
Number of subjects: 114
Study: 16799817

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Walking (W)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Jogging (J)
Number of subjects: 15
Study: 12749506

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 11066466

Group type: EXPERIMENTAL
Intervention: Home-based motivational interviewing sessions (median of four sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (routine smoking guidance)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home-based motivational interviewing sessions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postnatal telephone questionnaire
Number of subjects: 100
Study: 9264092

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages consumed ad lib prior to testing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Caffeine abstinence
Number of subjects: 24
Study: 8473428

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (n = 10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No therapy (n = 8)
Number of subjects: 18
Study: 3784284

Group type: EXPERIMENTAL
Intervention: Potassium citrate (30 to 80 mEq/day, usually 60 mEq/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sodium alkali (as bicarbonate or citrate, 60 to 118 mEq/day)
Number of subjects: 18
Study: 30371283

Group type: EXPERIMENTAL
Intervention: Cystatin C (Cys-C)
Number of subjects: 4965
Study: 27043416

Group type: COMPARATOR
Intervention: Usual care (n=305)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: NBS group (n=300)
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: NBS + DBS group (n=296)
Number of subjects: 901
Study: 24633934

Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg daily for 24 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 160
Study: 23612435

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Suboxone)
Number of subjects: 77
Study: 21097765

Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies (reminders, educational outreach, audit and feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored guideline implementation strategies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard guideline implementation strategies
Number of subjects: 0
Study: 18004064

Group type: EXPERIMENTAL
Intervention: C.E.R.A. administered once every 2 weeks (Q2W) via subcutaneous or intravenous injection
Number of subjects: 336

Group type: COMPARATOR
Intervention: Epoetin administered at current dose, route, and administration interval (once to three times weekly)
Number of subjects: 336
Study: 16488335

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1347
Study: 14696659

Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 425

Group type: COMPARATOR
Intervention: TPS implants
Number of subjects: 425
Study: 12422907

Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin for 7 days
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 10636336

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic/pharmacodynamic (PK/PD) modelling
Number of subjects: 0
Study: 7724390

Group type: COMPARATOR
Intervention: Conventional therapy (digoxin, furosemide, low dose ACE inhibition)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Staged therapy (maximal tolerated ACE inhibition, PGE1 therapy, outpatient dobutamine)
Number of subjects: 236
Study: 1837942

Group type: EXPERIMENTAL
Intervention: Ceftazidime (CFZ)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cefonicid (CFN)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Spectinomycin (SPM)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Piperacillin (PP)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Doxycycline (DXC)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Repeated treatment (C3)
Number of subjects: 111
Study: 7107969

Group type: EXPERIMENTAL
Intervention: Penfluridol, maximum dose 140 mg per week
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chlorpromazine, maximum dose 7350 mg per week
Number of subjects: 59